Lysine: Follow-up report on Higge's lawsuit against Ipin patent infringement

May 16, 2015, Meihua Bio announced that Meihua intends to acquire 100% of Ippin's interestThe matter has been approved by the 11th meeting of the 7th Board of Directors of the Company and the first interim shareholders' meeting in 2015, approved by the CSRC and approved by the Ministry of Commerce for centralized examination and approval of the operators of the transactionMf
On March 18, 2015, the Company issued a "Announcement on the Description of Media Reports by Meihua Biotech Group Co., Ltdon media coverage of the infringement of Ipin Biolyly inflightus" (Notice No2015-027) and paid active attention to the follow-up progressMf
On May 14, 2015, the Company received a copy of the civil suit filed by Ipsin BioThe documents show that the Hohhot Intermediate People's Court has filed a patent infringement case against CJ First Sugar Co., Ltd(hereinafter referred to as Hijie, plaintiff in the case) against Inner Mongolia Ipin Biotech Co., Ltd(hereinafter referred to as Inner Mongolia Yipin, defendant in the case of Aipin Bio-owned subsidiary) for invention patent infringement, noThe basic facts of the case are as follows:Mfkon March 5, 2015, plaintiff Hij filed a lawsuit with the Hohhot Intermediate People's Court regarding the infringement of the products of the defendant, Nemon IplynlyainMf
The claim is:Mfk1Order the defendant Inner Mongolia Ibin Biotech Co., Ltdto immediately stop the production, sale, promise to sell the infringement of the plaintiff No200980103315.6 invention patent rights, product approval number for the Mengfeeding Word (2014) 080002 L-Lyssine sulfate salt products;Mf
2Destroy L-lysine sulfate products that infringe the patent rights of the invention No200980103315.6, and the product approval number is Mon-Fed (2014) 080002;Mf
3Order the defendant Inner Mongolia Ibin Biotech Co., Ltd immediately stop the production, sale, promise to sell the infringement of the plaintiff No 200980103315.6 invention patent L-lysine hydrochloride products; Mf
　　4 Destruction of L-lysine hydrochloride products that infringe the plaintiff's patent rights for invention No 200980103315.6; Mf
　　5 Order the defendant Inner Mongolia Ibin Biotech Co., Ltd to immediately stop the production or use of nucleic acid molecules, carriers, transformations and destroy the relevant products that infringe the plaintiff's patent No 200980103315.6; Mf
　　6 Destroy the proprietary equipment used to produce the product protected by the plaintiff's invention patent rights No 200980103315.6 or to implement the method of patent protection; Mf
　　7 The defendant was ordered to compensate the plaintiff for the economic loss and the reasonable expenditure incurred by the plaintiff to stop the infringement totalling RMB 10,000; Mf
　　8 The defendant was ordered to bear the costs of the proceedings in the present case Mf
　　Facts and Reasons: Mfk 2014, plaintiff Hij found that the market suspected of infringing its patent number ZL200980103315.6 (hereinafter referred to as patent 315) invention patent lysine sulfate products and lysine hydrochloride products, the production of approved text number is the molysse word (2014) 08002, by the defendant, The defendant Moinei salinus The plaintiff entrusted his agent to entrust the suspected infringing product L-lysine sulfate, which was notarized to the Institute of Bioengineering of the Academy of Military Medical Sciences, to conduct a nucleic acid sequence analysis, and the test results showed that the promoter contained in the suspected infringing product was the same as the initiation subsequence of the plaintiff's Patent Renovation No 315 Therefore, the plaintiff argued that the alleged infringing product used nucleic acid molecules, carriers or converters in patent 315 granted patent protection by the plaintiff and the method of producing lysine, and that the defendant's conduct constituted infringement, and for that reason filed an action with the Hohhot Intermediate People's Court Mf
　　Meihua said that the above-mentioned litigation matters will pay close attention to the impact of the above-mentioned litigation on the issue of shares to purchase assets, timely follow up on the new progress of the matter, and in accordance with the relevant requirements of the Shanghai Stock Exchange Stock Listing Rules, actively fulfill the obligation of information disclosure, timely disclosure to the outside world, to draw the attention of investors to investment risks Mfk on May 16, 2015, Meihua Bio announced that Meihua intends to acquire 100% of Ipn's interest The matter has been approved by the 11th meeting of the 7th Board of Directors of the Company and the first interim shareholders' meeting in 2015, approved by the CSRC and approved by the Ministry of Commerce for centralized examination and approval of the operators of the transaction Mf
　　On March 18, 2015, the Company issued a "Announcement on the Description of Media Reports by Meihua Biotech Group Co., Ltd on media coverage of the infringement of Ipin Biolyly inflightus" (Notice No 2015-027) and paid active attention to the follow-up progress Mf
　　On May 14, 2015, the Company received a copy of the civil suit filed by Ipsin Bio The documents show that the Hohhot Intermediate People's Court has filed a patent infringement case against CJ First Sugar Co., Ltd (hereinafter referred to as Hijie, plaintiff in the case) against Inner Mongolia Ipin Biotech Co., Ltd (hereinafter referred to as Inner Mongolia Yipin, defendant in the case of Aipin Bio-owned subsidiary) for invention patent infringement, no The basic facts of the case are as follows: Mfk on March 5, 2015, plaintiff Hij filed a lawsuit with the Hohhot Intermediate People's Court regarding the infringement of the products of the defendant, Nemon Iplynlyain Mf
　　The claim is: Mfk 1 Order the defendant Inner Mongolia Ibin Biotech Co., Ltd to immediately stop the production, sale, promise to sell the infringement of the plaintiff No 200980103315.6 invention patent rights, product approval number for the Mengfeeding Word (2014) 080002 L-Lyssine sulfate salt products; Mf
　　2 Destroy L-lysine sulfate products that infringe the patent rights of the invention No 200980103315.6, and the product approval number is Mon-Fed (2014) 080002; Mf
　　3 Order the defendant Inner Mongolia Ibin Biotech Co., Ltd immediately stop the production, sale, promise to sell the infringement of the plaintiff No 200980103315.6 invention patent L-lysine hydrochloride products; Mf
　　4 Destruction of L-lysine hydrochloride products that infringe the plaintiff's patent rights for invention No 200980103315.6; Mf
　　5 Order the defendant Inner Mongolia Ibin Biotech Co., Ltd to immediately stop the production or use of nucleic acid molecules, carriers, transformations and destroy the relevant products that infringe the plaintiff's patent No 200980103315.6; Mf
　　6 Destroy the proprietary equipment used to produce the product protected by the plaintiff's invention patent rights No 200980103315.6 or to implement the method of patent protection; Mf
　　7 The defendant was ordered to compensate the plaintiff for the economic loss and the reasonable expenditure incurred by the plaintiff to stop the infringement totalling RMB 10,000; Mf
　　8 The defendant was ordered to bear the costs of the proceedings in the present case Mf
　　Facts and Reasons: Mfk 2014, plaintiff Hij found that the market suspected of infringing its patent number ZL200980103315.6 (hereinafter referred to as patent 315) invention patent lysine sulfate products and lysine hydrochloride products, the production of approved text number is the molysse word (2014) 08002, by the defendant, The defendant Moinei salinus The plaintiff entrusted his agent to entrust the suspected infringing product L-lysine sulfate, which was notarized to the Institute of Bioengineering of the Academy of Military Medical Sciences, to conduct a nucleic acid sequence analysis, and the test results showed that the promoter contained in the suspected infringing product was the same as the initiation subsequence of the plaintiff's Patent Renovation No 315 Therefore, the plaintiff argued that the alleged infringing product used nucleic acid molecules, carriers or converters in patent 315 granted patent protection by the plaintiff and the method of producing lysine, and that the defendant's conduct constituted infringement, and for that reason filed an action with the Hohhot Intermediate People's Court Mf
　　Meihua said that the above-mentioned litigation matters will pay close attention to the impact of the above-mentioned litigation on the issue of shares to purchase assets, timely follow up on the new progress of the matter, and in accordance with the relevant requirements of the Shanghai Stock Exchange Stock Listing Rules, actively fulfill the obligation of information disclosure, timely disclosure to the outside world, to draw the attention of investors to investment risks Mf
Share it on feed